Burden of metabolic dysfunction-associated steatohepatitis, with and without metabolic syndrome, obesity, or diabetes.

Elliot B Tapper¹, Taylor Ryan², Dave Lewandowski², Jessamine P Winer-Jones², Machaon Bonafede², Yestle Kim³

¹Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.

²Real World Evidence, Veradigm, Chicago, IL, USA.

³Health Economics and Outcomes Research, Madrigal Pharmaceuticals, Inc, West Conshohocken, PA, USA. ykim@madrigalpharma.com.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is commonly comorbid with metabolic syndrome; however, MASH can occur in the absence of metabolic syndrome. This retrospective cohort study evaluated the patient characteristics, healthcare utilization, and healthcare costs among patients with MASH with and without metabolic syndrome, obesity, and type 2 diabetes/elevated fasting…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.